Inventor

MARIGO MAURO

DK42 patents

⚠️ This page may combine multiple inventors who share the name “MARIGO MAURO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

MARIGO MAURO

H LUNDBECK AS

1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

Macrocycles as PDE1 inhibitors

1 H-pyrazolo[4,3-B]pyridines as PDE1 inhibitors

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Antibodies specific for hyperphosphorylated tau and methods of use

1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors

Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors

2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Prodrugs of modulators of the NMDA receptor

Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines

Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines

Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines

2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer&#39;s disease

2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors

Modulators of the NMDA receptor

LUNDBECK & CO AS H

2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer&#39;s disease

2-amino 6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors

Tricyclic imidazole compounds as PDE10 inhibitors

2-arylimidazole derivatives as PDE10A enzyme inhibitors

(3-aryl-1H-1,2,4-triazol-5-yl)-linked heterocycle derivatives

ENDOGENA THERAPEUTICS INC

Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium

Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium

N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases

PUESCHL ASK

(3-aryl-1H-1,2,4-triazol-5-yl)-linked heterocycle derivatives

(2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives

KEHLER JAN

Tricyclic imidazole compounds as PDE10 inhibitors

Püschl Ask

Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors

2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease

2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease